Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era
about
Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma.A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absentAbsolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphomaA Low Lymphocyte-to-Monocyte Ratio Predicts Unfavorable Prognosis in Pathological T3N0 Rectal Cancer Patients Following Total Mesorectal Excision.Analysis of prognostic factors in lymphoma patients with bone marrow involvement: a single center cohort study.Prognostic performance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: an updated meta-analysis of eleven reports.The derived neutrophil to lymphocyte ratio is an independent prognostic factor in patients with diffuse large B-cell lymphoma.Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma.Prognostic significance of lymphocyte-to-monocyte ratio in diffuse large B-cell lymphoma: a systematic review and meta-analysis.Regulatory myeloid cells: an underexplored continent in B-cell lymphomas.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.CD19(+) CD20(-) CD27(hi) IL-s10-producing B cells are overrepresented in R-CHOP-treated DLBCL patients in complete remission.Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.Prognostic effect of peripheral blood cell counts in advanced diffuse large B-cell lymphoma treated with R-CHOP-like chemotherapy: A single institution analysis.Should the cut-off values of the lymphocyte to monocyte ratio for prediction of prognosis in diffuse large B-cell lymphoma be changed in elderly patients?Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.The prognostic significance of CD11b+CX3CR1+ monocytes in patients with newly diagnosed diffuse large B-cell lymphoma.Prognostic significance of clinical presentation, induction and rescue treatment in 42 cases of canine centroblastic diffuse large B-cell multicentric lymphoma in the United Kingdom.B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity.Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy.The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.
P2860
Q33413210-7F253867-5684-4188-9361-21A213E0FF90Q33701858-07DB396A-8A71-4011-9C7B-2E45EA5EF682Q33945770-1F1E9918-7B13-42C7-8E67-EF6917CCC957Q34798062-9EC81779-5B1E-41F4-AD8A-F7C0107B2F5DQ35739526-765AD8B0-6759-4751-B086-B3E307D95A61Q35959252-6C25FA85-90DA-48CA-A651-745371386C2DQ36940100-EBDA6583-DB9E-4B1F-ABAB-FD8A4831467FQ37507473-3CEAF125-D23D-4C6F-AB2A-7D0FA2A60D01Q37746065-BDC9E9EE-E238-4F9D-BD28-A21CFF090314Q38757931-6346B6C8-B48A-4F10-8597-B35DBCCEE146Q38850729-2BFCE70B-B1D9-4FAB-BBED-88E538BDB132Q38897604-0C53C406-12BF-4554-BCA2-B7FB0CC82E48Q39423479-9D94A5D7-796C-49C4-9749-3BA67303255BQ39641273-69F1C98F-8F56-43F8-AFA0-63DAA8971F7CQ39720114-6A2C39C0-30B6-438F-BE7F-0A9DF1695513Q40678767-8AAE2DFE-0958-4606-8C64-6F5F145AB029Q40859968-F0FF41C8-A872-4890-A56F-8F3AA76055E2Q41148150-D0891468-0461-469E-A1FB-5AF348F45AF1Q41428549-9B9DCA6B-1C36-4261-A229-6C5F8BE5B463Q43114005-2850A6A2-8B44-406E-920B-DE9202B8FEBBQ43754838-B145E7EA-FD54-4483-A84A-9B1F0923FD59Q45216334-A2006EBE-8166-469A-B46B-7201F28D7DB3Q47151518-847066A8-B405-425C-9934-0BEE3CB594F9Q48359633-EBB3CF97-2E7C-4C3D-8367-5D52C0EFDB4AQ50545382-8AEC0D45-8789-4364-8614-D663C532F051Q53090405-C398120C-F6AE-4539-A4EC-AD8F9AE71D52Q54957513-D8CCD3EC-BF45-472C-9212-E5616822349D
P2860
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@ast
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@en
Monocyte count at diagnosis is ...... e pre- and post-rituximab era.
@nl
type
label
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@ast
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@en
Monocyte count at diagnosis is ...... e pre- and post-rituximab era.
@nl
prefLabel
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@ast
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@en
Monocyte count at diagnosis is ...... e pre- and post-rituximab era.
@nl
P2093
P2860
P50
P1433
P1476
Monocyte count at diagnosis is ...... he pre- and post-rituximab era
@en
P2093
Aaron Polliack
Dina Attias
Eliana Valentina Liardo
Irit Avivi
Luigi Marcheselli
Maura Brugiatelli
Noam Benyamini
Tamar Tadmor
P2860
P304
P356
10.3324/HAEMATOL.2013.088161
P50
P577
2013-08-09T00:00:00Z